Vanda Pharmaceuticals (VNDA) EPS (Weighted Average and Diluted) (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly EPS (Weighted Average and Diluted) of -$0.82 in Q1 2026, up 65.69% quarter-over-quarter from -$2.39 in Q4 2025, and down 64.0% year-over-year from -$2.28 in Q1 2025.
Vanda Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 17 years deep, the most recent figure standing at -$0.82 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 64.0% year-over-year to -$0.82; the TTM figure through Mar 2026 stood at -$4.05 (down 432.89% YoY), while the FY2025 annual figure was -$3.74, down 1033.33% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.82 for Q1 2026 at Vanda Pharmaceuticals, up from -$2.39 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.12 in Q4 2022 to a low of -$2.39 in Q4 2025.
- A 5-year average of -$0.28 and a median of -$0.08 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) surged 154.55% in 2023 and tumbled 3878.18% in 2024, its largest moves.
- Vanda Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.12 in 2022, then slumped by 141.67% to -$0.05 in 2023, then tumbled by 80.0% to -$0.09 in 2024, then tumbled by 2555.56% to -$2.39 in 2025, then surged by 65.69% to -$0.82 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.82, -$2.39, and -$0.38 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -0.82 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.82 |
| Dec 31, 2025 | -2.39 |
| Sep 30, 2025 | -0.38 |
| Jun 30, 2025 | -0.46 |
| Mar 31, 2025 | -0.50 |
| Dec 31, 2024 | -0.09 |
| Sep 30, 2024 | -0.09 |
| Jun 30, 2024 | -0.08 |
| Mar 31, 2024 | -0.07 |
| Dec 31, 2023 | -0.05 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.03 |
| Mar 31, 2023 | 0.06 |
| Dec 31, 2022 | 0.12 |
| Sep 30, 2022 | 0.06 |
| Jun 30, 2022 | 0.05 |
| Mar 31, 2022 | -0.11 |
| Dec 31, 2021 | 0.12 |
| Sep 30, 2021 | 0.14 |
| Jun 30, 2021 | 0.17 |
| Mar 31, 2021 | 0.15 |
| Dec 31, 2020 | 0.15 |
| Sep 30, 2020 | 0.11 |
| Jun 30, 2020 | 0.16 |
| Mar 31, 2020 | 0.01 |
| Dec 31, 2019 | 0.08 |
| Sep 30, 2019 | 1.84 |
| Jun 30, 2019 | 0.21 |
| Mar 31, 2019 | -0.01 |
| Dec 31, 2018 | 0.19 |
| Sep 30, 2018 | 0.13 |
| Jun 30, 2018 | 0.09 |
| Mar 31, 2018 | 0.06 |
| Dec 31, 2017 | -0.04 |
| Sep 30, 2017 | -0.10 |
| Jun 30, 2017 | -0.03 |
| Mar 31, 2017 | -0.17 |
| Dec 31, 2016 | -0.01 |
| Dec 31, 2015 | -0.35 |
| Dec 31, 2014 | 1.77 |
| Sep 30, 2014 | -0.04 |
| Jun 30, 2014 | -0.64 |
| Mar 31, 2014 | -0.79 |
| Dec 31, 2013 | -0.23 |
| Sep 30, 2013 | -0.17 |
| Jun 30, 2013 | -0.11 |
| Mar 31, 2013 | -0.15 |
| Dec 31, 2012 | -0.23 |
| Sep 30, 2012 | -0.19 |
| Jun 30, 2012 | -0.28 |
| Mar 31, 2012 | -0.28 |
| Dec 31, 2011 | -0.20 |
| Sep 30, 2011 | -0.11 |
| Jun 30, 2011 | -0.05 |
| Mar 31, 2011 | 0.00 |
| Dec 31, 2010 | 0.07 |
| Sep 30, 2010 | 0.11 |
| Jun 30, 2010 | 0.04 |